VNDA Vanda: Margin resik

Vanda Pharma (VNDA) - logo korporat

Strategic partnerships and the acquisition of CNS licenses are driving growth for Vanda Pharmaceuticals (VNDA). Annual net margins visualize this effect, where -119.90 captures a new level. Developments in neurochemistry and sleep research strengthen the firm's position, although patent dependency and the battle against generics create certain risks despite a stable liquidity reserve.

Vanda (VNDA) - Rentabilitas dodolan resik saka 04.07.2022 nganti 19.11.2026

Vanda (VNDA) - rincian metrik lan laporan keuangan

- rega saham lan prakiraan rega para ahli:
- data kapitalisasi saham perusahaan:
Analisis umum perusahaan:Vanda Pharmaceuticals Inc. - VNDA
Produk dadi Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals (VNDA) is integrating robotic molecule screening for CNS treatments, which is expected to optimize operating expenses and enhance overall business efficiency. Analyzing the level of commercial profitability, the investor assesses the net profit margin relative to total revenue, allowing for a determination of the company's actual ability to convert sales into bottom-line income and confirm the fundamental stability of the model.